Merrimack Reports Third Quarter 2022 Financial Results
Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) [(“Merrimack” or the “Company”)] today announced its third quarter 2022 financial results for the period ended September 30, 2022
By AP News
Published - Nov 03, 2022, 04:49 PM ET
Last Updated - Mar 18, 2024, 02:40 PM EDT
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov 3, 2022--
Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) [(“Merrimack” or the “Company”)] today announced its third quarter 2022 financial results for the period ended September 30, 2022.
“During the third quarter we continued to see the benefits of reduced operating expenses,” said Gary Crocker, Chairman of Merrimack's Board of Directors. “We will continue to monitor developments in Ipsen’s Onivyde® (irinotecan liposomal injection) program and Elevation’s seribantumab program.”
Third Quarter 2022 Financial Results
